Shenzhen New Industries Biomedical Asset Resilience Ratio
Shenzhen New Industries Biomedical asset resilience ratio. Shenzhen New Industries Biomedical (300832) has an Asset Resilience Ratio of 9.95% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 300832 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Shenzhen New Industries Biomedical (2020–2024)
Asset resilience ratio of Shenzhen New Industries Biomedical from 2020 to 2024. This chart shows how Shenzhen New Industries Biomedical's Asset Resilience Ratio has changed over time. Read Shenzhen New Industries Biomedical (300832) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Shenzhen New Industries Biomedical's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Shenzhen New Industries Biomedical total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥953.21 Million | 9.95% |
| Total Liquid Assets | CN¥953.21 Million | 9.95% |
Asset Resilience Insights
- Limited Liquidity: Shenzhen New Industries Biomedical maintains only 9.95% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Shenzhen New Industries Biomedical Industry Peers by Asset Resilience Ratio
Compare Shenzhen New Industries Biomedical's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
HOB Biotech Group Corp Ltd
SHG:688656 |
Medical Devices | 2.62% |
|
L&C Bio Co. Ltd
KQ:290650 |
Medical Devices | 2.14% |
|
Applied BioCode
TW:6598 |
Medical Devices | 9.75% |
|
Oncosil Medical Ltd
AU:OSL |
Medical Devices | 0.00% |
|
Cleo Diagnostics Ltd
AU:COV |
Medical Devices | 94.64% |
|
Radiant Innovation
TWO:3373 |
Medical Devices | 0.82% |
|
Impedimed Ltd
AU:IPD |
Medical Devices | 46.15% |
|
Memphasys Ltd
AU:MEM |
Medical Devices | 0.00% |
Shenzhen New Industries Biomedical Asset Resilience Ratio by Year (2020–2024)
Shenzhen New Industries Biomedical asset resilience ratio by year from 2020 to 2024. The table below shows the annual Asset Resilience Ratio data for Shenzhen New Industries Biomedical.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 17.92% | CN¥1.72 Billion ≈ $252.20 Million |
CN¥9.62 Billion ≈ $1.41 Billion |
-10.74pp |
| 2023-12-31 | 28.65% | CN¥2.36 Billion ≈ $344.75 Million |
CN¥8.22 Billion ≈ $1.20 Billion |
-11.46pp |
| 2022-12-31 | 40.11% | CN¥2.81 Billion ≈ $411.73 Million |
CN¥7.01 Billion ≈ $1.03 Billion |
-5.63pp |
| 2021-12-31 | 45.74% | CN¥2.81 Billion ≈ $410.68 Million |
CN¥6.14 Billion ≈ $897.82 Million |
+2.39pp |
| 2020-12-31 | 43.35% | CN¥2.30 Billion ≈ $336.58 Million |
CN¥5.31 Billion ≈ $776.39 Million |
-- |
About Shenzhen New Industries Biomedical
Shenzhen New Industries Biomedical Engineering Co., Ltd., engages in the research, development, production, and sale of clinical laboratory instruments and in vitro diagnostic reagents to hospitals in China and internationally. It offers immunoassay machine, biochemistry/electrolyte, integrated system, lab automation, molecular diagnostics, hemolumi and rapid test solutions. The company was found… Read more